BRII-297

Brii Biosciences Limited · Phase 1 active Small molecule

At a glance

Generic name	BRII-297
Also known as	Escalating doses of BRII-297
Sponsor	Brii Biosciences Limited
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Study of BRII-297 in Healthy Adult Subjects (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

BRII-297 CI brief — competitive landscape report
BRII-297 updates RSS · CI watch RSS
Brii Biosciences Limited portfolio CI